And, in doing so, we argue, they serve to capture value from biomedical innovation in ways that limit global access to medicines while simultaneously entrenching the dominance of high-income countries, lead firms and the interests of investors.Owain Williamsmsparke@ucsc.eduMatthew Sparke...